3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
NET
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Sarcoma
4
Thyroid Cancer, Papillary
2
Salivary Gland Neoplasms
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Breast Neoplasms
2
Brain Neoplasms
2
Wilms Tumor
1
Sarcoma, Ewing
1
Recurrence
1
Prostatic Neoplasms
1
Neuroendocrine Tumors
1
Neuroblastoma
1
Nephroma, Mesoblastic
1
Neoplasm Metastasis
1
Melanoma
1
Medulloblastoma
1
Lymphoma, Large-Cell, Anaplastic
1
Head and Neck Neoplasms
1
Glioma
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Central Nervous System Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
5
Gemcitabine
5
Cisplatin
5
Carboplatin
5
Fluorouracil
4
Filgrastim
4
Cetuximab
3
fludarabine
2
cemiplimab
2
belinostat
2
atezolizumab
2
Temozolomide
2
Riluzole
2
Peripheral Blood Stem Cell Transplantation
2
Oncolytic Virotherapy
2
Nivolumab
2
Ipilimumab
2
Cyclophosphamide
2
Bortezomib
2
AH 111585
2
zanidatamab
1
vocimagene amiretrorepvec
1
trifluridine tipiracil drug combination
1
trastuzumab deruxtecan
1
toripalimab
1
spartalizumab
1
seribantumab
1
selpercatinib
1
repotrectinib
1
poly ICLC
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Head and Neck Neoplasms
×
entrectinib
×
Sarcoma
×
Clear all
NCT02568267
2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2
Active not recruiting
534 enrolled
1 FDA